Staphylococcus aureus remains a leading cause of bacterial infections worldwide, ranging from skin and soft tissue infections to more severe conditions such as bacteremia, meningitis, pneumonia, osteomyelitis, and endocarditis. The high morbidity and mortality associated to S. aureus infections is due largely to its methicillin resistant form (MRSA), which was historically associated exclusively with hospitalacquired infections, but subsequently spread also to the community posing new threats and challenges. (…)The overall purpose of this project is to develop a molybdenum coating with biocidal activity against S. aureus to reduce contamination on environment surfaces, and therefore contribute to a local and global MRSA control.
